A genetics company committed to providing genetic analysis products and services that translate genomic science into superior solutions for the biomedical research, molecular medicine, agricultural, and non-invasive prenatal testing markets.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
This stock has a very high market potential for the Trisomy 21 market. the molecular diagnostics industry is about a 50 Billion dollar industry and if they have a good product pipeline for this NON-invasive prenatal testing, the sky is the limit. They current have two products in the pipeline, one for RhD and one for Downs.
Downs is a multi billion dollar market worldwide.
Another reason to be excited about owning shares of SQNM: iSEQ Pathogen Typer, to help identify viruses and other pathogens quickly, in hours, not days; Copy Number Variation (CNV) or how Human genes play a role in the disease process and individual drug response; the launch of Epi-designer, to aid researchers in the identification of mutated genes; the release of Onco-gene Mutation panel in Q408 to help identify patterns of genes associated with specific cancers; the licensing of Optical Nanopore Sequency technology from Harvard to quickly identify a whole genome quickly and inexpensively, for around $1,000.00 and other technologies aiding in the pursuit of personalized medicine
Funny you have no rating...